Nocturia - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Nocturia - Pipeline Review, H1 2019’, provides an overview of the Nocturia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nocturia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nocturia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nocturia

- The report reviews pipeline therapeutics for Nocturia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Nocturia therapeutics and enlists all their major and minor projects

- The report assesses Nocturia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Nocturia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Nocturia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Nocturia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ferring International Center SA

Sanwa Kagaku Kenkyusho Co Ltd

Vantia Ltd

Ferring International Center SA

Sanwa Kagaku Kenkyusho Co Ltd

Vantia Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nocturia - Overview

Nocturia - Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nocturia - Overview

Nocturia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Nocturia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nocturia - Companies Involved in Therapeutics Development

Ferring International Center SA

Sanwa Kagaku Kenkyusho Co Ltd

Vantia Ltd

Nocturia - Drug Profiles

(acetaminophen + ibuprofen) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-7035 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

desmopressin acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

desmopressin acetate ODT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FE-201836 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fedovapagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SK-1404 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nocturia - Dormant Projects

Nocturia - Discontinued Products

Nocturia - Product Development Milestones

Featured News & Press Releases

Nov 09, 2018: NOCDURNA (desmopressin acetate) sublingual tablets now available by prescription in US for treatment of nocturia due to nocturnal polyuria

Oct 29, 2018: Avadel presents data on Quality of Life Improvement in patients on NOCTIVA at American Urological Association Western Annual Meeting

Oct 15, 2018: Avadel Pharmaceuticals presents data for NOCTIVA at 2018 American Urogynecologic Society Annual Scientific Meeting

Sep 28, 2018: Avadel Pharmaceuticals announces Journal of Urology Publication of phase 3 data on NOCTIVA

Aug 29, 2018: New Data on NOCTIVA Presented at the 2018 International Continence Society Meeting

May 18, 2018: Avadel to Present Late-Breaker Data and Product Theater Forum at the 2018 American Urological Association Annual Meeting

May 01, 2018: Avadel Launches NOCTIVA, the First and Only FDA-Approved Treatment for Nocturia Due to Nocturnal Polyuria

Apr 03, 2018: Avadel Pharmaceuticals Announces Acceptance of Late-Breaker Presentation for NOCTIVA at the 2018 American Urological Association

Oct 05, 2017: Avadel Pharmaceuticals Announces Data Presentation for Noctiva at The American Urogynecologic Societys Annual Scientific Meeting

Aug 08, 2017: Ferring Pharmaceuticals: The Scottish Medicines Consortium Approves Use of NOQDIRNA (oral lyophilisate desmopressin), the First Licensed Treatment for Nocturia due to Idiopathic Nocturnal Polyuria in Adults

Aug 07, 2017: Noqdirna is accepted for restricted use within NHS Scotland

Feb 13, 2017: Scottish Medicines Consortium Rejects Noqdirna For Use Within NHS Scotland

Oct 20, 2016: FDA Advisory Committee Recommends Approval of SER120 (desmopressin nasal spray)

May 08, 2016: Studies Demonstrate New Options to Help Prevent and Treat Nocturia

May 03, 2016: Allergan Presents New Data on SER120 at the American Urological Association Meeting in San Diego

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Nocturia, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by ...

List of Tables

Number of Products under Development for Nocturia, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Nocturia - Pipeline by Ferring International Center SA, H1 2019

Nocturia - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2019

Nocturia - Pipeline by Vantia Ltd, H1 2019

Nocturia - Dormant Projects, H1 2019

Nocturia - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Nocturia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by ...

List of Figures

Number of Products under Development for Nocturia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports